Fig. 6From: EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patientsSubgroup analysis according to TP53 status. a Progression-free survival (PFS) stratified by T790M relative mutation purity (RMP)-low and RMP-high patients in TP53 wild-type population (P = 0.024, log-rank test). b PFS stratified by T790M RMP-low and RMP-high patients in TP53 mutated population (P = 0.074, log-rank test)Back to article page